Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4712 in advanced solid tumors
NCT06993116Phase 1Active, not recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-4712 in solid tumor (advanced stage), sponsored by Hengrui Therapeutics. Primary endpoints: Dose Limited Toxicity at 21 days and Adverse Events at 24 months. Started Jun 2025; status: active, not recruiting.
02
Drugs
SHR-4712
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06993116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06993116.